90P - Prognostic value of vitamin-D level in non-metastatic breast cancer patients in Saudi Arabia

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Breast Cancer, Early Stage
Presenter Shereef Elsamany
Citation Annals of Oncology (2016) 27 (suppl_9): ix19-ix29. 10.1093/annonc/mdw575
Authors S. Elsamany1, A. Alzahrani2, O. Elemam1, S. Elmorsy2, N. Abo Hashish3
  • 1Oncology, Oncology Centre Mansura University, 13115 - Dakahlia/EG
  • 2Oncology, King Abdullah Medical City, 57657 - Mecca/SA
  • 3Research, King Abdullah Medical City, 57657 - Mecca/SA



Deficiency of vitamin-D was associated with poor outcome in several studies across different tumour types. The present study aims to assess the prevalence and prognostic value of vitamin D deficiency among breast cancer patients in a single institution in Saudi Arabia.


In this retrospective study, we screened patients who presented with non-metastatic breast cancer to King Abdullah Medical City, Saudi Arabia from June 2011 to December 2014. We checked baseline vitamin-D level before starting systemic therapy in addition to other clinicopathological factors. Low vitamin-D was defined as vitamin-D level less than 30 ng/ml. The relations of vitamin-D level with clinicopathological factors were assessed using independent samples t-test. Chi-square test was used to assess the correlation of those variables with relapse risk while Cox regression analysis was used to check for the relation of vitamin- D level as a continuous variable with the risk of relapse.


We screened 286 patients with non-metastatic breast cancer. Baseline vitamin-D levels were available for 141 patients. Mean and median vitamin-D levels were 16.9± 9.1 ng/ml and 15.9 ng/ml, respectively. Mean vitamin-D level was significantly lower in ER-negative compared to ER-positive patients (14.2±7.1 vs. 18.6±9.7 ng/ml respectively, p = 0.007), in PR-negative compared to PR-positive patients (14.5 ±6.9 vs. 18.8 ±9.9 ng/ml respectively, p = 0.006) and in patients with lymphovascular invasion (LVI) compared to those with no LVI (15.4 ±8.3 vs. 21.2± 9.8 ng/ml, p = 0.001). Vitamin-D level as a continuous variable was not associated with the risk of disease relapse (hazard ratio= 0.99; 95% Confidence interval: 0.94-1.05, p = 0.69). Using chi-square test, LVI (p = 0.021), ER-negative (p 


Low vitamin- D level was prevalent among the studied breast cancer patients. Low vitamin- D level was associated with ER/PR-negative phenotype and with positive LVI. Baseline vitamin- D level was not linked with the risk of disease relapse.

Clinical trial indentification

Legal entity responsible for the study

King Abdullah Medical City, Saudi Arabia


King Abdullah Medical City, Saudi Arabia


All authors have declared no conflicts of interest.